Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.
Epistemonikos ID: b5a20e850d33d5f582a044ba43fb2827a2d9d78a
First added on: Feb 19, 2024